Clinical Trial Update: Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating gemcitabine, irinotecan, and panitumumab in advanced/metastatic biliary tract adenocarcinoma completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Irinotecan (Irinotecan)
• Panitumumab (panitumumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Biliary Cancer, Cholangiocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-06-18